| Chris Blackwell
PhD, Non-Executive Director.
Dr Blackwell joined the Board of AGI Therapeutics
plc in July 2006. He is Chief Executive Officer
of Vectura plc. Vectura is a UK-based pulmonary
product development company listed on London's Alternative
Investment Market. Dr. Blackwell joined Vectura
in October 2002 and was appointed CEO in February
2004. He led the company's flotation in July 2004,
raising £20m, and more recently, in June 2006,
raised £45m in a secondary placing.
Dr. Blackwell trained as a research scientist at
the University of Bath, where he completed his doctorate
in 1988. He joined Glaxo Research and Development
in 1988 as a Clinical Pharmacologist and progressed
to a management role before moving to Hoffman La-Roche,
becoming UK Director, Global Project Management
in 1996. Dr. Blackwell joined Scotia Pharmaceuticals
plc in 1998, where he served as Executive Director,
Drug Development
|
|
